Compare Globus Medical Inc. Class A Common Stock (GMED) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Microsoft — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Microsoft trades at $531.14 (market cap $4.04T). The key difference: Microsoft is far larger — about 394.1× Globus Medical Inc. Class A Common Stock's market cap, and Microsoft pays a 0.72% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Microsoft for 142 Days on average.
| GMED | MSFT | |
|---|---|---|
Market Cap | $10.25B | $4.04T |
Volume | 1,108,124 | 23,799,223 |
Sector | Health | Technology |
52-Week High | $96.82 | $543.45 |
52-Week Low | $58.33 | $352.83 |
Typical Hold Time | 0 Days | 142 Days |
Enterprise Value | $9.76B | $4.02T |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Microsoft (MSFT) trades at $533.69, down 1.38% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $530 and resistance at $544, while valuation metrics like P/E of 30.28 reflect premium pricing. Recent analyst coverage remains overwhelmingly positive with 82% buy ratings and a $574.50 consensus price target, indicating 7.6% upside potential from current levels.
Outlook remains favorable with AI-driven growth catalysts from Azure and Copilot, though risks include elevated capital expenditures and competitive pressures. The company's strong cash flow generation ($136.16B operating cash flow in 2025) and declining debt-to-asset ratio (6.97% in 2025) provide financial stability. Investors should monitor Q3 2026 earnings against the $4.72 EPS expectation for continued momentum validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
